A promising anti-cancer compound is gaining attention from the investors community and showing great promise in fighting cancer.
Propanc Health Group Corporation (OTCBB: PPCH)It believes that it has discovered a way to lower the average tumor weight for pancreatic and ovarian cancers. A third patent was filed by the company based on research into its proenzyme PRP which targets cancer stem cell elimination while sparing normal stem cell.
CSCs (cancer stem cells) are immortal cells that initiate tumors. They can self-renew and transform into other types of cells. These stem cells can be found in many solid tumours. They are believed to be responsible for tumor development, initiation, and recurrence.
Experiments were carried out by the University of Jaen in Spain and the University of Granada, Spain. The experiments used isolated CSCs taken from patients.
Researchers at the university were able to confirm that several important EMT genes (epithelial-to-mesenchymal transition), from CSCs, are significantly lower by using multiple experimental methods. According to the partners EMT is when cells develop migratory, invasive, and stem-like properties. EMT can be associated with normal bodily processes, but it also triggers metastasis to cancer progression.
“After conducting these experiments, PRP is quite dramatically suppressing the metastatic potential of CSCs by regulating the EMT process. This is relevant because in CSCs, the EMT machinery is working very hard to maintain their metastatic potential compared with ‘normal’ cancer cells,”Dr. Macarena Peran is a lecturer at the University of Jaen and is also the laboratory manager.
Dr. Peran said that. “because the EMT seems to be suppressed in several different ways, there is more than enough to justify developing a new compound, which usually requires only one pathway to be inhibited.”Dr. Peran said that the results are encouraging.
Propanc’s chief executive officer James Nathanielsz agrees.
“Not only have we now shown that PRP halts a fundamental mechanism by which cancer grows and spreads in order to reduce the risk of relapse, but we can now turn our attention toward developing new compounds that enhance these clinical effects.”
For more information, please visit www.propanc.com.
